Home » Newsletters » BioWorld Science

BioWorld Science

May 23, 2008

View Archived Issues

GenPhar avian influenza virus vaccines protective against H5N1challenge in mice

J-591 development proceeds after phase IIa study in androgen-independent prostate cancer

Studies of AER-002 in cystic fibrosis and COPD yield mixed results

Enclomiphene increases testosterone in men with adult idiopathic hyogonadotrophic hypogonadism

Improved adverse effect profile of Ono's novel anticholinergic bronchodilator

Global clinical SIR-Spheres microspheres trial launched in colorectal cancer

Newron completes patient enrollment in phase III safinamide study

Ardea provides update for non-nucleoside reverse transcriptase inhibitor program

Ariad initiates phase I trial of AP-24534 in patients with hematological cancers

Indevus licenses Canadian rights for Sanctura XR to Allergan

Wyeth and Progenics present preliminary results for two Relistor studies

Antitussive activity of SCH-255288 in several models of experimental cough

Novel 5-ASA derivative alleviates colonic inflammation and pain in mouse models

NPL-2005 awarded U.S. orphan drug status for fragile X syndrome

Lundbeck acquires European commercialization rights to Flurizan

New phase III data reported for Q-8003IR dual opioid therapy

Arixtra approved for new indication in Japan

Bayer Yakuhin obtains additional indication approval in Japan for Fludara

Encouraging phase I interim data reported for CG-0070 in bladder cancer

New therapeutic options for thrombotic disorders described in recent patents

Recent Roche and GSK patents disclose novel antiatherosclerotic agents

Novel treatments for neurological disorders reported in recent patent literature

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Laigo raises €11.5M seed money for targeted protein degradation
BioWorld Science
Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by...